Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Clin Neurol Neurosurg ; 196: 105990, 2020 09.
Article in English | MEDLINE | ID: mdl-32526487

ABSTRACT

OBJECTIVE: Moderate to severe spasticity is commonly reported in Multiple Sclerosis (MS) and its management is still a challenge. Cannabinoids were recently suggested as add-on therapy for the treatment of spasticity and chronic pain in MS but there is no conclusive scientific evidence on their safety, especially on cognition and over long periods. The aim of this prospective pilot study was to assess the long-term effects of a tetrahydrocannabinol-cannabidiol (THC/CBD) oromucosal spray (Sativex®) on cognition, mood and anxiety. PATIENTS AND METHODS: An extensive and specific battery of neuropsychological tests (Symbol Digit Modalities Test-SDMT, California Verbal Learning Test-CVLT, Brief Visuospatial Memory Test-BVMT; PASAT-3 and 2; Free and Cued Selective Remind Test-FCSRT, Index of Sensitivity of Cueing-ISC) was applied to longitudinally investigate different domains of cognition in 20 consecutive MS patients receiving Sativex for spasticity. The primary endpoint was to assess any variation in cognitive performance. Secondary outcomes regarding mood and anxiety were investigated by means of Beck Depression Inventory (BDI) and Hamilton Anxiety Rating Scale (HAM-A). Any change in patients' spasticity was evaluated using the 0-10 Numerical Rating Scale (NRS). RESULTS: Twenty per protocol patients were followed up and evaluated at baseline, 6 and 12 months. Domains involving processing speed and auditory verbal memory significantly improved within the first 6 months of therapy (SDMT: p < 0.001; CVLT: p = 0.0001). Mood and anxiety did not show any significant variation. Additionally, the NRS score significantly improved since the beginning (p < 0.0001). CONCLUSIONS: These results are encouraging in supporting possible long-term benefits of Sativex on cognition and a wider role than symptom alleviator. Further studies on larger groups of patients would be necessary in order to test this intriguing possibility.


Subject(s)
Cannabidiol/pharmacology , Cannabidiol/therapeutic use , Cognition Disorders/drug therapy , Cognition/drug effects , Dronabinol/pharmacology , Dronabinol/therapeutic use , Multiple Sclerosis/complications , Muscle Spasticity/drug therapy , Parasympatholytics/pharmacology , Adult , Aged , Cannabidiol/administration & dosage , Cognition Disorders/etiology , Dronabinol/administration & dosage , Drug Combinations , Female , Humans , Male , Middle Aged , Multiple Sclerosis/psychology , Muscle Spasticity/etiology , Neuropsychological Tests , Oral Sprays , Parasympatholytics/administration & dosage , Parasympatholytics/therapeutic use , Pilot Projects , Prospective Studies , Single-Blind Method , Young Adult
2.
J Am Osteopath Assoc ; 118(8): 531-536, 2018 Aug 01.
Article in English | MEDLINE | ID: mdl-30073336

ABSTRACT

CONTEXT: Research on the effect of osteopathic manipulative therapy (OMTh; manipulative care provided by foreign-trained osteopaths) on chronic symptoms of multiple sclerosis (MS) is lacking. OBJECTIVE: To evaluate the effect of OMTh on chronic symptoms of MS. METHODS: Patients with MS who were evaluated at the neurology clinic at Genoa University in Italy were recruited for this study. Participants received 5 forty-minute MS health education sessions (control group) or 5 OMTh sessions (OMTh group). All participants completed a questionnaire that assessed their level of clinical disability, fatigue, depression, anxiety, and quality of life before the first session, 1 week after the final session, and 6 months after the final session. The Extended Disability Status Scale, a modified Fatigue Impact Scale, the Beck Depression Inventory-II, the Beck Anxiety Inventory, and the 12-item Short Form Health Survey were used to assess clinical disability, fatigue, depression, anxiety, and quality of life, respectively. RESULTS: Twenty-two participants were included in the study (10 in the control group and 12 in the OMTh group). In the OMTh group, statistically significant improvements in fatigue and depression were found 1 week after the final session (P=.002 and P<.001, respectively). An increase in quality of life was also found in the OMTh group 1 week after the final session (P=.36). CONCLUSION: Results demonstrate that OMTh should be considered in the treatment of patients with chronic symptoms of MS.


Subject(s)
Manipulation, Osteopathic , Multiple Sclerosis/therapy , Adult , Anxiety/etiology , Depression/etiology , Fatigue/etiology , Fatigue/therapy , Female , Foreign Medical Graduates , Humans , Italy , Male , Middle Aged , Multiple Sclerosis/psychology , Retrospective Studies , Young Adult
3.
Neurol Sci ; 38(6): 1101-1104, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28150101

ABSTRACT

Delirium is an acute neuropsychiatric syndrome, very common in hospitalized people with medical and neurological conditions. The identification of delirium after stroke is not an easy task and validated psychometric instruments are needed to correctly identify it. We decided to verify if (1) formal training in DSM-V criteria is needed to correctly identify post-stroke delirium, (2) if the use of a brief psychometric instrument such as 4AT improves its identification, (3) the applicability of these scales in the stroke setting. In the first phase of this study we retrospectively studied 102 acute stroke patients in Stroke Units of San Martino Hospital (Genova, Italy) to evaluate delirium with clinical criteria, first by a neurologist without a formal training in DSM-V criteria and after training. Then, we enrolled 100 new acute stroke patients who underwent screening for delirium using 4AT scale and DSM-V criteria. In the first phase, DSM-V criteria training significantly increased the ability to capture delirium (5 vs. 15%). In the second phase, the 4AT was used for delirium screening revealing a 52% of cases of delirium, the same observed by the consensus diagnosis of two senior neurologists (that was 50%). In the second phase, the use of 4AT scale allowed to capture post-stroke delirium as well as the consensus diagnosis by two neurologists. The identification of post-stroke delirium is not an easy task and requires both formal training in DSM-V criteria as well as the application of brief scales, such as the 4AT.


Subject(s)
Delirium/diagnosis , Delirium/etiology , Stroke/complications , Acute Disease , Adult , Aged , Aged, 80 and over , Delirium/epidemiology , Diagnostic and Statistical Manual of Mental Disorders , Glasgow Coma Scale , Humans , Incidence , Middle Aged , Neuropsychological Tests , Prospective Studies , Retrospective Studies , Sensitivity and Specificity , Stroke/epidemiology , Young Adult
4.
Nutr Clin Pract ; 31(2): 186-90, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26869612

ABSTRACT

BACKGROUND: Wernicke encephalopathy (WE) is a medical emergency caused by thiamine deficiency, characterized by cerebellar ataxia, ophthalmoplegia, and cognitive disturbances that may progress to Korsakoff amnesia. We describe 2 patients with WE who needed high-dose and long-term treatment with thiamine to obtain neurological improvement and recovery. CASE DESCRIPTION: The first patient was a woman diagnosed with non-Hodgkin lymphoma. After a gastrointestinal infection, she developed depression, memory loss, disorientation, behavioral changes, and ataxic paraplegia. Brain magnetic resonance imaging (MRI) showed bilateral alterations in thalamic, frontal, and periaqueductal regions, suggestive of WE. The second patient was a man who lost 10 kg after surgical gastrectomy; he developed diplopia, ophthalmoplegia, cerebellar ataxia, lower limb paresthesias, and amnesia. A brain MRI demonstrated contrast enhancement of mammillary bodies, compatible with WE. OUTCOME: The patients were treated with intramuscular (IM) thiamine (1200 mg/d for 2 months and 900 mg/d for a month, respectively) with gradual cognitive and behavioral improvement and brain MRI normalization, while ataxia and oculomotion improved in following months. In both patients, thiamine was gradually reduced to IM 200 mg/d and continued for a year, without clinical relapses. CONCLUSIONS: There is no consensus about dosage, frequency, route, and duration of thiamine administration in WE treatment. Based on our cases, we recommend treating patients with WE with higher doses of IM thiamine for a longer time than suggested (900-1200 mg/d for 1-2 months, in our cases) and to gradually reduce dosage after clinical and radiological improvement, maintaining IM 200 mg/d dosage for at least 1 year.


Subject(s)
Wernicke Encephalopathy/diagnostic imaging , Wernicke Encephalopathy/drug therapy , Administration, Intravenous , Aged , Brain/diagnostic imaging , Dose-Response Relationship, Drug , Female , Humans , Injections, Intramuscular , Lymphoma, Non-Hodgkin/blood , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/diagnosis , Magnetic Resonance Imaging , Male , Middle Aged , Thiamine/administration & dosage , Thiamine/blood , Thiamine Deficiency/blood , Thiamine Deficiency/complications , Thiamine Deficiency/diagnosis , Thiamine Deficiency/drug therapy , Wernicke Encephalopathy/blood , Wernicke Encephalopathy/complications
5.
Hum Vaccin Immunother ; 10(7): 1969-73, 2014.
Article in English | MEDLINE | ID: mdl-25424806

ABSTRACT

Acute disseminated encephalomyelitis (ADEM) is an inflammatory, usually monophasic, immune mediate, demyelinating disease of the central nervous system which involves the white matter. ADEM is more frequent in children and usually occurs after viral infections, but may follow vaccinations, bacterial infections, or may occur without previous events. Only 5% of cases of ADEM are preceded by vaccination within one month prior to symptoms onset. The diagnosis of ADEM requires both multifocal involvement and encephalopathy and specific demyelinating lesions of white matter. Overall prognosis of ADEM patients is often favorable, with full recovery reported in 23% to 100% of patients from pediatric cohorts, and more severe outcome in adult patients. We describe the first case of ADEM occurred few days after administration of virosomal seasonal influenza vaccine. The patient, a 59-year-old caucasic man with unremarkable past medical history presented at admission decreased alertness, 10 days after flu vaccination. During the 2 days following hospitalization, his clinical conditions deteriorated with drowsiness and fever until coma. The magnetic resonance imaging of the brain showed multiple and symmetrical white matter lesions in both cerebellar and cerebral hemispheres, suggesting demyelinating disease with inflammatory activity, compatible with ADEM. The patient was treated with high dose of steroids and intravenous immunoglobulin with relevant sequelae and severe neurological outcomes.


Subject(s)
Encephalomyelitis, Acute Disseminated/complications , Encephalomyelitis, Acute Disseminated/diagnosis , Influenza Vaccines/adverse effects , Nervous System Diseases/diagnosis , Anti-Inflammatory Agents/therapeutic use , Brain/diagnostic imaging , Brain/pathology , Encephalomyelitis, Acute Disseminated/drug therapy , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Influenza Vaccines/administration & dosage , Magnetic Resonance Imaging , Male , Middle Aged , Radiography , Steroids/therapeutic use , Vaccines, Virosome/administration & dosage , Vaccines, Virosome/adverse effects
7.
Santiago de Chile; Chile. Pontificia Universidad Católica; 1996. 112 p.
Monography in Spanish | MINSALCHILE | ID: biblio-1542231
SELECTION OF CITATIONS
SEARCH DETAIL
...